Table 1.
Induction strategy | ||
---|---|---|
Variable | Chemotherapy (n=114) | Novel agent (n=110) |
Patients: | ||
Age, years, mean (SD) | 56 (9) | 55 (9) |
Female, % | 42 | 41 |
KPS, median: | 90 | 90 |
Diagnosis to SCT, d, mean (SD) | 232 (53) | 110 (82) |
Disease: | ||
ISS stage, med: | 2 | 2 |
Durie-Salmon stage, %: | ||
1: | 9 | 10 |
2: | 16 | 13 |
3: | 77 | 77 |
Isotype, %: | ||
IgG: | 58 | 51 |
IgA: | 24 | 23 |
Light chain only: | 13 | 25 |
IgD: | 5 | 1 |
Cytogenetics,%: | ||
Standard risk: | 74 | 74 |
High risk: | 26 | 26 |
Radiation, %: | 22 | 18 |